spacer
home > ebr > spring 2003 > signal transduction in breast cancer: silencing the cross-talk
PUBLICATIONS
European Biopharmaceutical Review

Signal Transduction in Breast Cancer: Silencing the Cross-Talk

Signal transduction pathways mediate the ability of cells to respond to hormonal and environmental stimuli. Diverse and rapid cellular responses to external stimuli may involve proliferation, differentiation, migration or programmed cell death. In the normal cell a tightly regulated cross-talk network between multiple independent and convergent pathways maintains the cell in a specific developmental and functional pathway. Aberrations in these signal transduction pathways can result in cellular transformation. Furthermore, experimental evidence suggests that pathway cross-talk augments the tumorigenic and metastatic potential of transformed cells. Additionally, cross-talk between diverse signal transduction pathways appears to play a critical role in the progression and therapeutic resistance of breast cancer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Frank E Jones, Department of Structural and Cellular Biology, Dr Matthew E Burow, Department of Medicine (Hematology & Medical Oncology), Department of Surgery, and Dr Steven M Hill, Department of Structural and Cellular Biology, at Tulane Cancer Center

Dr Frank E Jones undertook his post-doctoral training at Yale University within the Department of Pathology. He accepted a position as Assistant Professor at Tulane University in the Department of Structural and Cellular Biology in June 2001.

Dr Jones' research interests focus on the development of mouse models to study the molecular mechanisms contributing to metastatic breast, ovarian and prostate cancers.

Dr Matthew E Burow carried out his post-doctoral studies at the Tulane/Xavier Center for Bioenvironmental Research and was subsequently appointed as a Research Assistant Professor in the Department of Pharmacology in 2000. In 2002 Dr Burow accepted his current position as an Assistant Professor in the Section of Hematology and Medical Oncology, Department of Medicine, with an appointment as an Adjunct Assistant Professor in the Department of Surgery. His primary research interests focus on understanding the molecular mechanisms that control oestrogen receptor mediated gene expression and anti-oestrogen resistance in breast carcinoma cells, as well as the way that cell survival and apoptotic signalling pathways regulate the progression of breast carcinoma to a hormone independent and drug resistant phenotype.

Dr Steven M Hill undertook his post-doctoral training at the University of Texas Health Sciences Center, San Antonio, in the Medical Oncology section of the Department of Medicine under the tutelage of the late Dr William L McGuire. Dr Hill joined Tulane University in 1989 as an Assistant Professor and is currently Professor of Structural and Cellular Biology at Tulane University Health Sciences Center and holds the Edmond and Lily Safra Chair for breast cancer research. Dr Hill's general research interests focus on defining the mechanisms of cross-talk between G-protein coupled receptor signalling pathways and steroid hormone receptor signalling pathways in breast cancer.
spacer
Dr Frank E Jones
spacer
spacer
spacer
Dr Matthew E Burow
spacer
spacer
spacer
Dr Steven M Hill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement